A Phase 1, Randomized, 3-way, Crossover Single Dose, Placebo, and Active Controlled Study to Evaluate the Effect of Intravenous Doses of GMI-1070 on QTc Intervals in Healthy African-American Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2016
At a glance
- Drugs Rivipansel (Primary) ; Moxifloxacin
- Indications Haematological malignancies; Intra-abdominal infections; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
- Focus Adverse reactions
- Sponsors Pfizer
- 12 Mar 2016 Results of QT/QTc interval effect (n=48) were presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 04 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.